The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Relapsing-remitting multiple sclerosis (RRMS) is an inflammatory and neurodegenerative disease. After two or more short courses of alemtuzumab (ALZ), an immune reconstitution is achieved, which long-term results in reduced disease activity. We aimed to investigate the effect of ALZ on measures of neurodegeneration (i.e., brain atrophy, and retinal layer thinning).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Mult Scler Relat Disord

Title: Multiple sclerosis and related disorders

Publisher: Elsevier BV

ISSN (Electronic): 2211-0356

ISSN (Print): 2211-0348

Publication date (Electronic): Nov 2024

Volume: 91

Affiliations

[1 ] Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska, Department of Neurology, Region Västra Götaland, SE-413 45 Gothenburg, Sweden. Electronic address: sofia.sandgren@vgregion.se.

[2 ] Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska, Department of Neurology, Region Västra Götaland, SE-413 45 Gothenburg, Sweden. Electronic address: lenka.novakova@vgregion.se.

[3 ] Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska, Department of Neurology, Region Västra Götaland, SE-413 45 Gothenburg, Sweden. Electronic address: anna.nordin@neuro.gu.se.

[4 ] Department of Neurology and Ophthalmology outpatient clinics, Hallands Hospital Kungsbacka, SE-434 80 Kungsbacka, Sweden. Electronic address: hemin.sabir@regionhalland.se.

[5 ] Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska, Department of Neurology, Region Västra Götaland, SE-413 45 Gothenburg, Sweden. Electronic address: markus.axelsson@neuro.gu.se.

[6 ] Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska, Department of Neurology, Region Västra Götaland, SE-413 45 Gothenburg, Sweden; Laboratory for Clinical Immunology, Sahlgrenska University Hospital, SE-413 46 Gothenburg, Sweden. Electronic address: clas.malmestrom@vgregion.se.

[7 ] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, SE-431 80 Mölndal, Sweden; Department of Neurodegenerative Disease, University College London (UCL) Queen Square Institute of Neurology, London, United Kingdom; United Kingdom (UK) Dementia Research Institute at University College London (UCL), London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, Hong Kong, China; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. Electronic address: henrik.zetterberg@clinchem.gu.se.

[8 ] Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska, Department of Neurology, Region Västra Götaland, SE-413 45 Gothenburg, Sweden. Electronic address: jan.lycke@neuro.gu.se.

Article

Publisher Item ID: S2211-0348(24)00470-X

DOI: 10.1016/j.msard.2024.105894

PubMed ID: 39293124

SO-VID: 76a93666-9dff-4162-8708-9f2a7f018750

History

Keywords: Alemtuzumab,Brain atrophy,Glial fibrillary acid protein,Neurofilament light,Relapsing-remitting multiple sclerosis,Retinal layer thinning

Data availability:

Keywords: Alemtuzumab, Brain atrophy, Glial fibrillary acid protein, Neurofilament light, Relapsing-remitting multiple sclerosis, Retinal layer thinning

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.